Covid-19, Immunogenicity, Microbiome, SARS-CoV-2, Vaccine
Conditions
Brief summary
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.
Interventions
We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
Sponsors
Korea University Guro Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* People assigned to get either BNT162b2 or ChAdOx1 vaccines * informed concents
Exclusion criteria
* Participants were excluded if they had a history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Taxonomic biomarkers predicting immune responses | before the administration of first-dose | This study aimed to analyze whether fecal microbiota composition before vaccination was associated with immmune response level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antibody titres after the first dose vaccination | 3weeks from the first-dose administration in BNT162b2 group, 8-12weeks from the first-dose administration in ChAdOx1 | This study aimed to analyze maximum immune response after first dose vaccination |
| Antibody titres after the second dose vaccination | 3 weeks from the second dose administration in both BNT162b2 and ChAdOx1 groups | This study aimed to analyze maximum immune response after second dose vaccination |
Countries
South Korea
Outcome results
None listed